Prostate Cell News | Science News

Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, a First-of-Its-Kind Treatment for Localized Prostate Cancer

January 9, 2026

[Alessa Therapeutics] Alessa Therapeutics announced that the US FDA has granted Fast Track designation for Enolen®, the Company’s lead product candidate for the treatment of low to intermediate risk, localized prostate cancer.

Butterfly Medical Announces Completion of Pivotal Trial for Minimally Invasive Treatment of Benign Prostatic Hyperplasia

January 9, 2026

[Butterfly Medical (BioSpace)] Butterfly Medical, developer of a non-surgical solution for benign prostatic hyperplasia (BPH), announced the successful completion of the final 12-month follow-up for all patients in its international pivotal clinical study. The landmark study was designed to evaluate the safety and efficacy of the Butterfly Prostatic Retraction Device, a first-line interventional therapy for BPH.

Sodium-Glucose Cotransporter 2 Inhibitors for Patients with Prostate Cancer Undergoing Hormone Therapy

January 9, 2026

[JAMA Oncology] In this cohort study with a target trial emulation design, sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering.

Uropathogenic Escherichia Coli Invade Luminal Prostate Cells via FimH-PPAP Receptor Binding

January 9, 2026

[Nature Microbiology] Researchers developed a 2D mouse stem cell-derived prostate epithelial organoid model. In the organoid model, 5α-dihydrotestosterone promoted differentiation of basal into luminal cells, while transcriptomic analyses validated the model in comparison to 3D models and mouse prostate tissue.

Unraveling the Microbial Landscape in Prostate Cancer: Pathogenesis to Therapy

January 8, 2026

[NPJ Biofilms and Microbiomes] The authors examine microbes from the skin, oral cavity, gut, urinary tract, and the prostate cancer microenvironment, summarizing how these communities affect prostate cancer initiation, progression, and therapeutic response.

Unraveling the Microbial Landscape in Prostate Cancer: Pathogenesis to Therapy

January 7, 2026

[NPJ Biofilms and Microbiomes] The authors examine microbes from the skin, oral cavity, gut, urinary tract, and the prostate cancer microenvironment, summarizing how these communities affect prostate cancer initiation, progression, and therapeutic response.

PEAK1 Promotes Prostate Cancer Progression and Docetaxel Resistance by Mediating the Polarization of Tumor-Associated Macrophages

January 7, 2026

[European Journal of Medical Research] Researchers investigated the role and mechanisms of pseudopodium-enriched atypical kinase (PEAK) 1 in prostate cancer progression and docetaxel resistance.

Circular RNA-Based Therapy Targeting Metabolic Vulnerability of Fatty Acid Synthesis Overcomes Castration-Resistant Prostate Cancer

January 7, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified circUTRN, an androgen receptor-inhibited circRNA that is upregulated following neoadjuvant hormonal therapy and downregulated in prostate cancer tissues.

Breaking Barriers in Prostate Cancer: The mRNA Vaccine Breakthrough and What Comes Next

January 7, 2026

[NPJ Vaccines] The authors explore mRNA-based vaccines as a promising immunotherapy in prostate cancer.

SOX4-Mediated Post-Transcriptional Suppression of PTEN via Mir-106b∼25 Cluster Contributes to Prostate Cancer Aggressiveness

January 6, 2026

[Molecular Cancer Research] Scientists revealed that SOX4 expression was increased in patients with prostate cancer with low PTEN levels, and the expression of SOX4 and PTEN was inversely correlated in patients with prostate cancer.

Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer

January 6, 2026

[Cancer Research] Researchers demonstrated that inhibiting histone H4-lysine 20 methyltransferases SUV4-20H1 and SUV4-20H2 induced synthetic lethality in combination with the TOP2 poison etoposide in prostate cancer.

TDP2 Drives Immune Evasion and Metastatic Progression in Prostate Cancer

January 6, 2026

[PloS One] Researchers identified tyrosyl-DNA phosphodiesterase 2 (TDP2) as a key regulator within the tumor microenvironment and suggested its potential utility as both a prognostic biomarker and therapeutic target in prostate cancer.